Article

Mechanisms of lower gastrointestinal toxicity caused by tyrosine kinase inhibitors

2020-01-01

Abstract excerpt

Lower gastrointestinal (GI) toxicity – manifested as diarrhoea – often occurs in cancer patients undergoing treatment with tyrosine kinase inhibitors (TKIs). TKIs used for chronic myeloid leukaemia have a differential propensity to cause lower GI toxicity, with bosutinib having the highest incidence. Management strategies include treatment with non-specific anti-diarrhoea drugs, such as loperamide, which can be in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f6f1ca77-bd36-5828-b026-b6411e3272ae
DOI: 10.17638/03085962

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of lower gastrointestinal toxicity caused by tyrosine kinase inhibitorsDOI 10.17638/03085962Read

A Transcriptomic Approach to Elucidate the Mechanisms of Gefitinib-Induced Toxicity in Healthy Human Intestinal OrganoidsSemantic proximity Read

The differentiation state of small intestinal organoid models influences prediction of drug-induced toxicitySemantic proximity Read

Evaluation of the risk of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors with cultured intestinal stem cells originated from crypts in humans and monkeys.Semantic proximity Read

New insights into the mechanisms underlying 5-fluorouracil-induced intestinal toxicity based on transcriptomic and metabolomic responses in human intestinal organoidsSemantic proximity Read

Therapeutic potential of flavonoids in gastrointestinal cancer: Focus on signaling pathways and improvement strategies (Review)Semantic proximity Read

Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and CancerSemantic proximity Read

THE ROLE OF POTASSIUM CHANNELS IN THE PATHOGENESIS OF GASTROINTESTINAL CANCERS AND THERAPEUTIC POTENTIALSemantic proximity Read

Validation of an MPS based intestinal cell culture model for the evaluation of drug-induced toxicitySemantic proximity Read

Electrolyte disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity Read

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.Semantic proximity Read

A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor.Semantic proximity Read

Inhibition of EGFR/ErbB does not protect against <i>C. difficile</i> toxin BSemantic proximity Read